Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 14/20 | 0.86 |
| ▸ | CTSL | P07711 | 4/20 | 0.70 |
| ▸ | CTSB | P07858 | 4/20 | 0.70 |
| ▸ | CTSK | P43235 | 3/20 | 0.70 |
| ▸ | CTSS | P25774 | 1/20 | 0.64 |
| ▸ | CTSC | P53634 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27305643 | 1.00 | USP30 (0.86) | USP30CTSLCTSBCTSKCTSS | |
| SCHEMBL18115519 | 0.92 | USP30 (1.00) | USP30CTSLCTSBCTSKCTSS | |
| SCHEMBL6851774 | 0.82 | CTSL (1.00) | USP30CTSLCTSBCTSKCTSS | |
| SCHEMBL6851697 | 0.81 | CTSB (1.00) | USP30CTSLCTSBCTSKCTSS | |
| SCHEMBL6858432 | 0.77 | CTSL (0.66) | USP30CTSLCTSBCTSKCTSS | |
| Cyanamide SCHEMBL6859700 | 0.77 | CTSB (0.92) | USP30CTSLCTSBCTSKCTSS | |
| SCHEMBL21324958 | 0.77 | CTSB (0.93) | USP30CTSLCTSBCTSKCTSS | |
| SCHEMBL18115550 | 0.77 | USP30 (1.00) | USP30CTSLCTSBCTSKCTSS | |
| SCHEMBL6858886 | 0.76 | CTSB (1.00) | USP30CTSLCTSBCTSKCTSS | |
| SCHEMBL7009469 | 0.76 | CTSB (1.00) | USP30CTSLCTSBCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123483-A1 | Method and composition for treating obesity by targeting cathespin | NMPI, LLC | 2007-05-31 | — | — | US | disclosed |
| US-20070123483-A1 | Method and composition for treating obesity by targeting cathespin | NMPI, LLC | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123483-A1 | Method and composition for treating obesity by targeting cathespin | CTSS, PRKCSH, CTSG | USP30 1836/4885CTSL 16/4885CTSB 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.